Medicines Access Programs (MAP) are programs offered by pharmaceutical companies (sponsors) to facilitate deferred cost, cost-free or subsidised access to medicines for hospital patients before the implementation of relevant funding arrangements.
MAP include, but are not limited to, the following:
- Compassionate Use
- Expanded Access Programs
- Product Familiarisation Programs
- Cost-Share Programs
The following documents can be used to assist in fulfilling the Managing Medicines Access Programs: Guiding Principles for the governance of Medicines Access Programs in Australian Hospitals issued by CATAG in May 2015.
It is recommended that Medicines Access Programs (MAPs) or patient familiarisation programs (PFPs) as DTC decisions. The following documents are recommended for use by the DTC when participating in a MAP.
It is recommended by the CATAG Guiding Principles for Medicines Access Programs in Australian Public Hospitals that MAP reports from prescribers are collated by the DTC.
NSW TAG acknowledges the Western Australian Therapeutics Advisory Group in the development of these forms.